Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024:241-247

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.241247

Advances in Bioresearch

REVIEW ARTICLE

An Overview of Unraveling the Promise and Understanding The Potential of Pharmacogenomics

P. Vaishnavi Reddy, J. Anantha Lakshmi*, P. Salome Satyavani
Sri Venkateshewara College of Pharmacy, Madhapur, Hyderabad, Telangana, India-500081
*Corresponding author email: anusvcp@gmail.com

ABSTRACT
Pharmacogenomics, often used interchangeably with pharmacogenetics, explores how an individual's genetic makeup affects their response to medication. However, its scope has expanded to encompass the use of genomic technologies in drug development, dosage optimization, and personalized treatment strategies. Integrating principles from pharmacology and genomics, pharmacogenomics aims to enhance treatment outcomes, minimize adverse reactions, and elevate patient care by tailoring drug therapies to individuals. This review outlines key elements and goals of pharmacogenomics, including identifying genetic variations, advancing drug development, implementing personalized medicine approaches, refining drug selection, and integrating pharmacogenomic data into clinical decision-making. The field's historical background, technological advancements, critical genes and variants, clinical applications, benefits, challenges, and future prospects are also discussed. Pharmacists play a crucial role in pharmacogenomics, contributing to personalized medicine by interpreting genetic test results, tailoring drug therapy, educating patients, and collaborating with healthcare providers. Overall, pharmacogenomics holds promise for revolutionizing medical practices towards more precise and tailored approaches to drug therapy.
Keywords: *Pharmacogenomics, genetic makeup, personalized treatment strategies.*

Received 12.12.2023 Revised 18.01.2024 Accepted 23.02.2024

How to cite this article:
P. Vaishnavi Reddy, J. Anantha Lakshmi, P. Salome Satyavani. An Overview of Unraveling the Promise and Understanding The Potential of Pharmacogenomics. Adv. Biores., Vol 15 (2) March 2024: 241-247.

INTRODUCTION

Pharmacogenomics, a frequently used interchangeably with its precursor, pharmacogenetics, traditionally refers to investigating how an individual's genetic composition influences their reaction to a medication. However, a more encompassing interpretation of pharmacogenomics, which we can prefer, involves utilizing genomic technologies to explore and create innovative drugs, as well as fine-tuning drug dosage and selection for individual patients to enhance effectiveness while minimizing toxicity. [1-8]

It integrates concepts from pharmacology, focusing on the interaction of drugs with the body, and genomics, which examines an individual's entire set of genes.

Few critical elements of pharmacogenomics encompass:

1. The detection of genetic variations influencing drug responses
2. Crafting personalized medicine rooted in an individual's genetic profile
3. Refining the efficiency and safety of drug treatments

The objective of pharmacogenomics is to enhance treatment outcomes, minimize adverse reactions, and elevate overall patient care by customizing drug therapies to an individual's genetic traits. [8-13] This domain has the capacity to transform medical practices by advancing towards more tailored and precise methods in drug therapy.

Top of Form

The breadth and goals of pharmacogenomics involve a diverse set of aims related to understanding and applying genetic information within the realm of drug response. Here are key facets:

Identification of Genetic Variations

Examine and categorize genetic variances, such as single nucleotide polymorphisms (SNPs) and other variations, impacting drug metabolism, effectiveness, and safety. [14, 15]

Advancement in Drug Development
Improve the drug development process by integrating genetic data to identify potential responders and anticipate adverse reactions early in the development phase [16].
Personalized Medicine Approaches
Create and implement strategies for personalized medicine, considering an individual's genetic composition to customize drug treatments for optimal effectiveness and minimal side effects [17].
Enhanced Drug Selection
Refine drug selection and dosages based on genetic data to attain superior therapeutic results and diminish the risk of adverse reactions.
Clinical Decision Support Integration
Incorporate pharmacogenomic data into clinical decision-making processes, guiding healthcare professionals in prescribing the most suitable medications for individual patients. [18]
Disease Management Utilization
Explore the application of pharmacogenomics in managing chronic diseases, refining treatment regimens, and enhancing patient outcomes.
Risk Anticipation
Devise tools for predicting an individual's risk of adverse drug reactions or treatment failure based on their genetic profile, enabling pre-emptive adjustments to treatment plans.
Education and Awareness Promotion
Advance education and awareness among healthcare professionals, researchers, and the public regarding the importance of pharmacogenomics and its potential impact on healthcare. [19]
Ethical Considerations Addressing
Tackle ethical, legal, and social implications associated with pharmacogenomic testing, ensuring responsible and equitable integration into healthcare practices.
Research Collaboration Encouragement
Promote collaboration among researchers, clinicians, pharmaceutical companies, and regulatory bodies to advance understanding of pharmacogenomics and facilitate its application in clinical practice. [20]
Healthcare Policy and Guideline Development
Contribute to the formulation of healthcare policies, guidelines, and standards incorporating pharmacogenomic information, ensuring its integration into routine clinical care.
Public Health Evaluation
Assess the public health impact of pharmacogenomics, including its potential to reduce healthcare costs, enhance patient outcomes, and improve the overall quality of healthcare delivery. [21]
In a clinical context, the objective of pharmacogenomics is to move beyond the conventional "**one drug fits all" or "one dose fits all**" approach, aiming for a more individualized selection and dosage of medications tailored to meet each patient's specific needs.
Historical Background
The origins of pharmacogenomics can be traced back to the mid-20th century when the observation of diverse responses to drugs prompted the concept of tailoring drug therapy to individuals. Landmark moments include the identification of genetic polymorphisms affecting drug metabolism, such as the recognition of acetylator phenotypes in the 1950s. The field gained momentum through advancements in molecular biology and the completion of the Human Genome Project in the early 21st century, providing a comprehensive map of the human genome. This molecular understanding laid the groundwork for contemporary pharmacogenomics, marking the onset of personalized medicine. [22-29]
Below is a concise summary of pivotal milestones in the evolution of pharmacogenomics:

1. Early Years (1950s-1990s): Pharmacogenomics originated from the intersection of pharmacology and genetics during this period. Initial studies focused on comprehending how genetic variations could impact drug metabolism and response, laying the foundation for subsequent advancements.
2. Discovery of Genetic Variants (1990s): Progress in molecular biology and genomics led to the identification of specific genetic variations influencing drug metabolism and efficacy. Examples include the role of the CYP2D6 gene in metabolizing drugs like codeine and variations in the TPMT gene affecting thiopurine metabolism.
3. Human Genome Project (2000): The completion of the Human Genome Project provided a comprehensive map of the human genome, facilitating the identification of genetic variants linked to drug responses—a crucial milestone in advancing pharmacogenomics.

4. Advancements in Genotyping Technologies (2000s): High-throughput genotyping technologies, such as microarrays and next-generation sequencing, emerged, enabling simultaneous analysis of multiple genetic variants. This facilitated large-scale pharmacogenomic studies, revealing associations between genetic variations and drug responses.
5. Pharmacogenomics Implementation (2010s): The focus shifted towards integrating pharmacogenomic data into clinical practice. Drug labels were updated to incorporate pharmacogenomic information, and institutions began implementing testing to guide drug prescribing. Initiatives like the Clinical Pharmacogenetics Implementation Consortium (CPIC) provided guidelines for translating genetic information into actionable clinical recommendations.
6. Precision Medicine Initiatives (2015-present): Pharmacogenomics became integral to precision medicine initiatives, tailoring treatments based on patients' genetic makeup. Global efforts were launched to incorporate pharmacogenomics into routine clinical care.
7. Technological Advances and Big Data (2020s): Continued progress in genomics, bioinformatics, and data analytics allowed researchers to explore complex interactions between genetics and drug response. Integration of big data and artificial intelligence enhanced the ability to analyse large datasets, uncovering subtle genetic influences on drug metabolism and efficacy.
8. Ongoing Research and Clinical Trials: Pharmacogenomics remains dynamic, with continual research and clinical trials exploring new genetic markers and their associations with drug responses. As our understanding of genetics and molecular biology expands, so does the potential for personalized medicine applications in pharmacogenomics.

Pharmacogenomic methodologies: Pharmacogenomic studies employ various methodologies to unravel the genetic underpinnings of drug responses. DNA sequencing techniques, including next-generation sequencing, enable the identification of genetic variations within crucial genes. Genotyping methods, such as polymerase chain reaction (PCR) and microarray analysis, facilitate the detection of specific genetic variants linked to drug metabolism.[30-34] Functional assays gauge the impact of genetic variations on enzyme activity and drug interactions. Additionally, bioinformatics plays a pivotal role in analysing data, interpreting results, and discovering novel associations between genetic markers and drug responses [30-37].

Table 1. Advantages and disadvantages of common pharmacogenomics technologies

Technology	Advantages	Disadvantages
Sanger sequencing	Established as the gold standard for verifying genetic variants	Tedious and time-consuming when handling large sample volumes.
Real time PCR	Conducts both amplification and analysis in a single step. Ideal for scrutinizing known variants and suitable for small target numbers	Incapable of uncovering novel pharmacogenomics biomarkers Often relies on proprietary primers and probes
Microarrays	Able to pinpoint tens of thousands of pharmacogenomics biomarkers across numerous samples per week, facilitating high- throughput workflows. Well-suited for clinical laboratories and capable of detecting both SNPs and CNVs	Limited in discovering novel pharmacogenomic variants since it's confined to the variants pre-included on the microarrays Demands high-quality samples, particularly for gene deletion and duplication analysis.

Critical Genes and Variants: Numerous pivotal genes and genetic variations play essential roles in pharmacogenomics. For example, cytochrome P450 (CYP) genes, like CYP2D6 and CYP3A4, influence the metabolism of a wide range of drugs. Genetic variants in VKORC1 and CYP2C9 are connected to warfarin responsiveness, while polymorphisms in TPMT are associated with the metabolism of thiopurine drugs.[35-37] As our comprehension deepens, these genes and variants continue to serve as vital indicators for predicting individual responses to different medications.

1. **CYP2D6:** Involved in metabolizing a diverse range of drugs, including many antidepressants and antipsychotics.
2. **CYP3A4 and CYP3A5:** Crucial for metabolizing various drugs, including specific statins and immunosuppressants.
3. **VKORC1 and CYP2C9**: Linked to the response to anticoagulant drugs such as warfarin.
4. **SLCO1B1**: Influences the response to statins used in lipid-lowering therapy.
5. **TPMT**: Essential for metabolizing thiopurine drugs used in conditions like leukaemia and inflammatory bowel disease.

Table 2: Examples of drugs with alterations in efficacy due to variation in specific genes [34-39].

Drug	Indication	Gene	Effect of Genes	Clinical Action to be Taken
Warfarin	Anticoagulant	CYP2C9, VKORC1	Variants can lead to increased bleeding risk	Adjust dosage based on genetic testing
Clopidogrel	Antiplatelet	CYP2C19	Poor metabolizers have reduced drug activation	Use alternative antiplatelet therapy if poor metabolizer is identified
Codeine	Pain management	CYP2D6	Ultra-rapid metabolizers risk morphine toxicity	Avoid codeine in ultra-rapid metabolizers
Trastuzumab	Breast cancer	HER2	Efficacy dependent on HER2 overexpression	Test for HER2 status before initiating treatment
Abacavir	HIV	HLA-B*5701	Hypersensitivity reactions in carriers	Screen for HLA-B*5701 allele before starting therapy
Imatinib	Chronic myeloid leukemia	BCR-ABL	Mutations can confer resistance	Monitor BCR-ABL mutations and adjust therapy accordingly
Tamoxifen	Breast cancer	CYP2D6	Poor metabolizers have reduced drug efficacy	Consider alternative therapies for poor metabolizers
5-Fluorouracil	Cancer	DPYD	DPD deficiency leads to severe toxicity	Reduce dose or use alternative treatment if DPD deficient
Carbamazepine	Epilepsy, bipolar disorder	HLA-B*1502	Increased risk of Stevens-Johnson syndrome	Genetic screening recommended in at-risk populations (e.g., Asian descent)
Statins	Hypercholesterolemia	SLCO1B1	Variants can increase risk of myopathy	Adjust dose or consider alternative statin if variant is present

Technologies in Pharmacogenomics

Few technologies that are applied in pharmacogenomics include genotyping and sequencing, microarray analysis, next generation sequencing and pharmacogenomic databases.[38-43]

1. **Genotyping and Sequencing**: Utilized for identifying specific genetic variations associated with drug response.
2. **Microarray Analysis**: Allows simultaneous analysis of multiple genetic variations, revealing patterns linked to drug metabolism and response. [44]
3. **Next-Generation Sequencing (NGS):** Enables high-throughput sequencing, aiding in identifying rare genetic variants.
4. **Pharmacogenomic Databases**: Resources like Pharm GKB offer valuable information on genetic variations and drug responses.

Clinical Applications of Pharmacogenomics

Pharmacogenomics has shifted from research to practical application in clinical settings [45]. The field's potential extends across therapeutic areas, promising a more tailored and effective approach to patient care. Few applications include:

1. **Personalized Drug Prescribing**: Tailoring drug prescriptions based on individual genetic profiles for optimized treatment outcomes.
2. **Dosing Optimization**: Adjusting drug dosages based on genetic factors to enhance efficacy and reduce adverse reactions.
3. **Cancer Treatment:** Identifying genetic markers to guide the selection of targeted therapies for cancer patients.
4. **Psychiatric Medications**: Optimizing the selection and dosing of antidepressants and antipsychotics based on genetic factors.
5. **Warfarin Dosing:** Using genetic information to determine appropriate warfarin doses for anticoagulation therapy.

Benefits of pharmacogenomics: By applying the pharmacogenomics in the clinical setting the benefits of it include:

1. More powerful medicines
2. Better and safer drugs
3. More accurate methods of determining appropriate drug dosages

4. Advanced screening for disease
5. Increased Efficacy
6. Better vaccines
7. Improvements in the drug discovery and approval process
8. Reduced Healthcare costs
9. Personalised medicine: tailored according to the patient's needs

Challenges in Pharmacogenomics

Despite its potential, pharmacogenomics faces challenges. Those include:

1. **Clinical Implementation**: Integrating into routine clinical practice and gaining physician adoption.
2. **Ethical and Legal Issues:** Addressing concerns related to privacy, consent, and potential misuse of genetic information.
3. **Data Interpretation**: Navigating the complexity of interpreting genetic data and translating it into actionable clinical decisions. [46]
4. **Limited Evidence for Some Drugs**: Insufficient evidence for the pharmacogenomics of certain drugs.
5. **Costs and Reimbursement**: Economic considerations related to testing costs and reimbursement for pharmacogenomic services.

Future Prospects in Pharmacogenomics

The future of pharmacogenomics holds exciting prospects which includes:

1. **Advancements in Technology**: Continued developments in genomic technologies for more accessible and affordable testing.
2. **Expanded Drug Coverage**: Increasing the number of drugs with well-established pharmacogenomic guidelines.
3. **Integration with Electronic Health Records (EHRs):** Seamless integration of genetic information into EHRs for real-time clinical decision support.
4. **Patient Empowerment**: Growing awareness and involvement of patients in their pharmacogenomic information and treatment decisions.
5. **International Collaboration:** Enhanced global collaboration among researchers, healthcare providers, and policymakers for standardized guidelines and practices [47].

Pharmacists in Pharmacogenomics

Pharmacists play a vital role in pharmacogenomics, contributing to personalized medicine in various ways. Those include.

- Interpret genetic test results and tailor drug therapy based on genetic variations.
- Assist in medication selection and dosing.
- Assess potential drug interactions.
- Educate patients about genetic testing implications.
- Collaborate with healthcare providers for comprehensive care plans. [48]
- Contribute to decision support systems.
- Stay informed about pharmacogenomic advances.
- Address ethical considerations in patient care.

Overall, pharmacists leverage their expertise to optimize therapeutic outcomes based on individual genetic profiles in the evolving field of pharmacogenomics.

CONCLUSION

Pharmacogenomics encompasses a transformative shift in drug therapy, transitioning from a generic approach to personalized medicine tailored to individual genetic characteristics. Genetic variability consistently influences drug responses, affecting metabolism and efficacy. Incorporating pharmacogenomic data into clinical decisions yields improved treatment outcomes across various therapeutic areas, with targeted therapies guided by genetic markers showing notable success, particularly in oncology and psychiatry. However, implementation hurdles, ethical concerns, and the need for standardized guidelines and education pose common challenges. Despite these obstacles, ongoing technological advancements, international collaboration, and pharmacist involvement hold promise for the widespread integration of pharmacogenomics into clinical practice. With its potential to optimize therapeutic outcomes and reshape healthcare, pharmacogenomics stands poised to revolutionize the future of medicine.

REFERENCES

1. Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464-467.
2. Pirmohamed, M. (2016). Pharmacogenetics and pharmacogenomics. British Journal of Clinical Pharmacology, 61(5), 447-454.
3. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., ... & Guchelaar, H. J. (2011). Pharmacogenetics: from bench to byte—an update of guidelines. Clinical Pharmacology & Therapeutics, 89(5), 662-673.
4. Bush, W. S., & Crosslin, D. R. (2014). Owning the stack: top-down efforts in pharmacogenomics implementation. Personalized Medicine, 11(5), 523-532.
5. Maddiboyina B, Ramaiah, Nakkala RK, Roy H (2023) Perspectives on cutting-edge nanoparticulate drug delivery technologies based on lipids and their applications. Chem Biol Drug Des. https://doi.org/10.1111/cbdd.14230.
6. Roy H, Maddiboyina B, Rahaman SA, Singh PK, Tripathi AK, Srivastava SK, Chaubey R, Theendra VK, Sankula KR (2023) Implementation and effect estimation by Taguchi orthogonal array design for Metoprolol Sustained Release Tablets. Smart Sci 11:649–660.
7. Maddiboyina B, Roy H, Nakkala RK, Gandhi S, Kavisri M, Moovendhan M. (2023). Formulation, optimization and characterization of raloxifene hydrochloride loaded PLGA nanoparticles by using Taguchi design for breast cancer application. Chem Biol Drug Des. 102(3), 457-470.
8. Jakka A, Balaji M. (2023). Nanoparticles for lung cancer: synthesis, characterization, and future perspectives. Nanomedicines: role in imaging, diagnosis and treatment of lung cancer. Woodhead Publishing India Pvt. Ltd. 1, 241-288.
9. Balaji M, Ramya Krishna N. (2023). Introduction to drug delivery systems: from conventional drug delivery systems to advanced drug delivery. Nanomedicines: role in imaging, diagnosis and treatment of lung cancer. Woodhead Publishing India Pvt. Ltd. 1, 1-40.
10. Schildcrout, J. S., Denny, J. C., Bowton, E., Gregg, W., Pulley, J. M., Basford, M. A., ... & Roden, D. M. (2012). Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clinical Pharmacology & Therapeutics, 92(2), 235-242.
11. Johnson, J. A. (2013). Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics, 14(7), 835-843.
12. Maddiboyina B, Roy H, Nakkala RK, Gandhi S, Kavisri M, Moovendhan M (2023) Formulation, optimization and characterization of raloxifene hydrochloride loaded PLGA nanoparticles by using Taguchi design for breast cancer application. Chem Biol Drug Des. https://doi.org/10.1111/cbdd.14222.
13. Nakkala, R. K., Maddiboyina, B., Bolisetti, S. C., & Roy, H. (2023). Duloxetine hydrochloride enteric-coated pellets in capsules with delayed release: formulation and evaluation. Smart Science. 11(3), 434–446.
14. Maddiboyina B, Roy H, Ramaiah M, Sarvesh CN, Kosuru SH, Nakkala RK, Nayak BS. (2023). Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs. Bull Natl Res Cent. 47, 95.
15. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343-350.
16. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279(15), 1200-1205.
17. Hughes, A. R., & Marsh, S. (2011). Pharmacogenomics: from candidate genes to genome-wide association. Clinical Pharmacology & Therapeutics, 89(6), 741-746.
18. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103-141.
19. Vasam M, Maddiboyina B, Talluri C, Alagarsamy S, Gugulothu B, Roy H (2023) Formulation, Characterization, and Taguchi Design Study of Eplerenone Lipid-Based Solid Dispersions Integrated with Gelucire. Bionanoscience. https://doi.org/10.1007/s12668-023-01102-4.
20. Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. (2020). Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release. 327, 500-511.
21. Maddiboyina B, Vanamamalai HK, Roy H, et al. (2023). Food and drug industry applications of microalgae Spirulina platensis: A review. J Basic Microbiol. 63(6), 573-583. doi:10.1002/jobm.202200704.
22. Sood S, Maddiboyina B, Rawat P, et al. (2021). Enhancing the solubility of nitazoxanide with solid dispersions technique: formulation, evaluation, and cytotoxicity study. J Biomater Sci Polym Ed. 32(4), 477-487.
23. Maddiboyina B, Nakkala RK, Sivaraman G (2022) Biomass-Derived Mesoporous Carbon Nanomaterials for Drug Delivery and Imaging Applications. In: Biomass-Derived Carbon Mater. pp 129–146.
24. V. Jhawat, M. Gulia, B. Maddiboyina, R. Dutt, S. Gupta, Fate and Applications of Superporous Hydrogel Systems: A Review, Curr. Nanomedicine. 10 (2020). https://doi.org/10.2174/2468187310999200819201555.
25. Maddiboyina B, Jhawat V, Desu PK, Gandhi S, Nakkala RK, Singh S. (2021). Formulation and evaluation of thermosensitive flurbiprofen in situ nano gel for the ocular delivery. J Biomater Sci Polym Ed. 32(12), 1584-1597.
26. Garg AK, Maddiboyina B, Alqarni MHS, et al. (2021). Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system. J Biomater Sci Polym Ed. 32(8), 1009-1023.

27. Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., ... & Relling, M. V. (2012). Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2012 update. Clinical Pharmacology & Therapeutics, 91(2), 321-326.
28. van Driest, S. L., Shi, Y., Bowton, E. A., Schildcrout, J. S., Peterson, J. F., Pulley, J., ... & Roden, D. M. (2014). Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clinical Pharmacology & Therapeutics, 95(4), 423-431.
29. Gulia M, Nishal S, Maddiboyina B, Dutt R, Kumar Desu P, Wadhwa R, (2023). Physiological Pathway, diagnosis and nanotechnology based treatment strategies for ovarian Cancer: A review. Med Omi, 8:100020.
30. Sim, S. C., & Ingelman-Sundberg, M. (2010). Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends in pharmacological sciences, 31(1), 4-9.
31. Maddiboyina B, Jhawat V, Nakkala RK, Desu PK, Gandhi S. (2021). Design expert assisted formulation, characterization and optimization of microemulsion based solid lipid nanoparticles of repaglinide. Prog Biomater. 10(4):309-320.
32. Roy H, Nayak BS, Maddiboyina B, Nandi S (2022) Chitosan based urapidil microparticle development in approach to improve mechanical strength by cold hyperosmotic dextrose solution technique. J Drug Deliv Sci Technol 76:103745.
33. Roy H, Srungarapati S, Gade NJ, Gummadi A, Marry Karunasree BK, Dakkumalla M, Maddiboyina B (2023) Citicoline loaded nanoemulsion enriched with D-alpha-Tocopherol acetate and protein: Formulation and in-silico study. J Drug Deliv Sci Technol 82:104340.
34. Maddiboyina BALAJI, Nakkala RK, Kokkilagadda VK. (2020) Preparation and evaluation of esomeprazole enteric coated tablets. Ijppr. 18(1):16–30.
35. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., ... & Guchelaar, H. J. (2011). Pharmacogenetics: from bench to byte-an update of guidelines. Clinical pharmacology & therapeutics, 89(5), 662-673.
36. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., ... & Giacomini, K. M. (2013). Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clinical pharmacology & therapeutics, 93(4), 324-325.
37. Pirmohamed, M. (2016). Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annual review of genomics and human genetics, 17, 155-169.
38. Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., ... & Ginsburg, G. S. (2013). Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 15(4), 258-267.
39. McLeod, H. L., & Evans, W. E. (2001). Pharmacogenomics: unlocking the human genome for better drug therapy. Annual review of pharmacology and toxicology, 41(1), 101-121.
40. Balaji M, Ramyakrishna N, Hanumanaik M. (2020). Formulation development and characterization of enteric coated tablets of Lansoprazole. Der Pharm Lett.12, 22–38.
41. Ananthalakshmi J, Balaji M. (2023). Nanoparticles for lung cancer: synthesis, characterization, and future perspectives. Nanomedicines: role in imaging, diagnosis and treatment of lung cancer. Woodhead Publishing India Pvt. Ltd.1, 241-288.
42. Balaji M, Ramya Krishna N. (2023). Introduction to drug delivery systems: from conventional drug delivery systems to advanced drug delivery. Nanomedicines: role in imaging, diagnosis and treatment of lung cancer. Woodhead Publishing India Pvt. Ltd.1, 1-40.
43. Maddiboyina, B., Shanmugapriya, J., Rasala, S., & Sivaraman, G. (2021). In bioinspired nanomaterials: Synthesis and emerging applications. Materials Research Forum LLC, 111, 63–95.
44. Singh S, Numan A, Maddiboyina B, et al. (2021). The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discov Today. 26(7), 1721-1727.
45. Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. Nature, 429(6990), 464-468.
46. Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., ... & Guchelaar, H. J. (2008). Pharmacogenetics: from bench to byte-an update of guidelines. Clinical pharmacology & therapeutics, 83(5), 781-787.
47. Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., ... & Green, E. D. (2018). Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clinical Pharmacology & Therapeutics, 103(5), 778-786.
48. Patel J, Kumar GS, Roy H, Maddiboyina B, Leporatti S, Bohara RA. (2024). From nature to nanomedicine: bioengineered metallic nanoparticles bridge the gap for medical applications. Discov Nano. 19, 85.